2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2560

Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2685

Factors Contributing to Capturing Positive Findings on Temporal Artery Biopsy: An Australian Experience from Two Rheumatology Referral Centers

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2226

Factors Contributing to Fracture in Pernicious Anemia Patients Presenting with Symptomatic Subacute Vertebral Compression Fractures

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2051

Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 2724

Farber Disease (Acid Ceramidase Deficiency): The First Natural History Study of This Rare Disease Involving Symptoms Which Can Mimic JIA

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2690

Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2433

Fatigue in Primary Sjögren’s Syndrome as a Manifestation of Heavier Disease Activity of Mucosa-Associated Lymphoid Tissue (MALT)

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2106

Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1975

Fibrates as Drugs with Senolytic and Autophagic Activity for Osteoarthritis Treatment

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2341

Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2102

First-line Antiretroviral Therapy with Tenofovir Produces Deleterious Effects on Bone and an Increase in Proinflammatory Cytokines Expression After 12 Months of Treatment in Naïve HIV Patients

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2647

Flares and Long-term Remission in Large-vessel Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-term Follow-up Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2616

Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 1969

FOXO1 Is Required for Human Osteoclast Differentiation

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2204

Fragility Fractures in a Community Setting: Clinical Characteristics, Care Gaps, and Outcomes

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].